ZEVASKYN™ (prademagene zamikeracel)
ZEVASKYN®, developed by Abeona Theapeutics, is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and paediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
The treament is supplied as a single-dose of up to twelve cellular sheets and consisting of patient's own, viable, gene-modified cells that contain functional copies of the COL7A1 gene, which express the collagen 7 (C7) protein.
| Approved by | Date of Approval | Therapeutic Approach | Route of Administration | EB Subtype |
| FDA | April 2025 | Gene therapies and combined gene/cell therapies | Skin grafting | RDEB |
Please note that a marketing authorisation by a national or international regulatory authority does not indicate whether the therapy or medication is available in a particular country or is reimbursed by a health insurance fund.
